Toader C, Tataru C, Munteanu O, Covache-Busuioc R, Serban M, Ciurea A
Int J Mol Sci. 2025; 25(24.
PMID: 39769374
PMC: 11728275.
DOI: 10.3390/ijms252413614.
von Essen M, Stolpe L, Bach Sondergaard H, Sellebjerg F
Front Immunol. 2024; 15:1487530.
PMID: 39650658
PMC: 11621209.
DOI: 10.3389/fimmu.2024.1487530.
Esposito A, Falco F, Scalia G, Gentile L, Spiezia A, Corsini G
Eur J Neurol. 2024; 32(1):e16536.
PMID: 39475271
PMC: 11625923.
DOI: 10.1111/ene.16536.
Arneth B
Int J Mol Sci. 2024; 25(16).
PMID: 39201672
PMC: 11354236.
DOI: 10.3390/ijms25168987.
Stys P, Tsutsui S, Gafson A, t Hart B, Belachew S, Geurts J
Front Cell Neurosci. 2024; 18:1426231.
PMID: 39161786
PMC: 11330826.
DOI: 10.3389/fncel.2024.1426231.
CD20+ T cells in monoclonal B cell lymphocytosis and chronic lymphocytic leukemia: frequency, phenotype and association with disease progression.
Rodrigues C, Laranjeira P, Pinho A, Silva I, Silva S, Coucelo M
Front Oncol. 2024; 14:1380648.
PMID: 38606091
PMC: 11007165.
DOI: 10.3389/fonc.2024.1380648.
Normalized circulating Tfh and Th17 associates with improvement in myasthenia gravis treated with ofatumumab.
Song X, He Y, Huo Y, Jiang H, Yu Y, Sun Y
Front Immunol. 2024; 15:1280029.
PMID: 38415260
PMC: 10898244.
DOI: 10.3389/fimmu.2024.1280029.
Treated and Untreated Primary Progressive Multiple Sclerosis: Walkthrough Immunological Changes of Monocytes and T Regulatory Cells.
Ipavec N, Rogic Vidakovic M, Markotic A, Pavelin S, Buljubasic Soda M, Soda J
Biomedicines. 2024; 12(2).
PMID: 38398067
PMC: 10887021.
DOI: 10.3390/biomedicines12020464.
Ocrelizumab associates with reduced cerebrospinal fluid B and CD20 CD4 T cells in primary progressive multiple sclerosis.
van Puijfelik F, Blok K, Klein Kranenbarg R, Rip J, de Beukelaar J, Wierenga-Wolf A
Brain Commun. 2024; 6(1):fcae021.
PMID: 38385000
PMC: 10881107.
DOI: 10.1093/braincomms/fcae021.
CD11c B cells in relapsing-remitting multiple sclerosis and effects of anti-CD20 therapy.
El Mahdaoui S, Hansen M, von Essen M, Hvalkof V, Holm Hansen R, Mahler M
Ann Clin Transl Neurol. 2024; 11(4):926-937.
PMID: 38332555
PMC: 11021659.
DOI: 10.1002/acn3.52009.
Regulatory T Cells in Multiple Sclerosis Diagnostics-What Do We Know So Far?.
Arneth B
J Pers Med. 2024; 14(1).
PMID: 38248730
PMC: 10821144.
DOI: 10.3390/jpm14010029.
A biphenotypic lymphocyte subset displays both T- and B-cell functionalities.
Zhang Y, Guo C, Zhou Y, Zhang W, Zhu Z, Wang W
Commun Biol. 2024; 7(1):28.
PMID: 38182721
PMC: 10770049.
DOI: 10.1038/s42003-023-05719-9.
Inflammation as common link to progressive neurological diseases.
Dias-Carvalho A, Sa S, Carvalho F, Fernandes E, Costa V
Arch Toxicol. 2023; 98(1):95-119.
PMID: 37964100
PMC: 10761431.
DOI: 10.1007/s00204-023-03628-8.
Immune monitoring of SARS-CoV-2-specific T cell and B cell responses in patients with multiple sclerosis treated with ocrelizumab.
Gross-Albenhausen E, Weier A, Velten M, Heider T, Chunder R, Kuerten S
Front Immunol. 2023; 14:1254128.
PMID: 37841269
PMC: 10569464.
DOI: 10.3389/fimmu.2023.1254128.
Immune reconstitution following alemtuzumab therapy is characterized by exhausted T cells, increased regulatory control of proinflammatory T cells and reduced B cell control.
von Essen M, Hojsgaard Chow H, Holm Hansen R, Buhelt S, Sellebjerg F
Front Immunol. 2023; 14:1249201.
PMID: 37744364
PMC: 10512074.
DOI: 10.3389/fimmu.2023.1249201.
CD73 regulates zoledronate-induced lymphocyte infiltration in triple-negative breast cancer tumors and lung metastases.
Petruk N, Siddiqui A, Tadayon S, Maatta J, Mattila P, Jukkola A
Front Immunol. 2023; 14:1179022.
PMID: 37533856
PMC: 10390692.
DOI: 10.3389/fimmu.2023.1179022.
Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab.
Nytrova P, Stastna D, Tesar A, Menkyova I, Posova H, Koprivova H
Front Immunol. 2023; 14:1149629.
PMID: 37398654
PMC: 10312310.
DOI: 10.3389/fimmu.2023.1149629.
Intrathecal CD8CD20 T Cells in Primary Progressive Multiple Sclerosis.
von Essen M, Talbot J, Hansen R, Hojsgaard Chow H, Lundell H, Siebner H
Neurol Neuroimmunol Neuroinflamm. 2023; 10(5).
PMID: 37369602
PMC: 10299852.
DOI: 10.1212/NXI.0000000000200140.
Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: Gene expression and protein profiles.
Fong C, Spencer J, Howlett-Prieto Q, Feng X, Reder A
Front Neurol. 2023; 14:1158487.
PMID: 37168665
PMC: 10166068.
DOI: 10.3389/fneur.2023.1158487.
Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab.
Pfeuffer S, Rolfes L, Ingwersen J, Pul R, Kleinschnitz K, Korsen M
Neurol Neuroimmunol Neuroinflamm. 2023; 10(3).
PMID: 37041077
PMC: 10091366.
DOI: 10.1212/NXI.0000000000200104.